Back to search

Article

Efficacy of Tenapanor in Managing Hyperphosphatemia and Constipation in Hemodialysis Patients: A Randomized Controlled Trial

2025-02-03

Abstract excerpt

<h4>Introduction</h4> Tenapanor is a minimally absorbed, small-molecule inhibitor of sodium/hydrogen exchanger 3 and thus suppresses sodium absorption in the gastrointestinal tract. It is approved by the FDA for the treatment of hyperphosphatemia in dialysis patients. This randomized controlled trial evaluated its efficacy in the treatment of hyperphosphatemia and constipation in hemodialysis patients. <h4>Methods...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2968de63-b983-5c47-9ba6-b9605620e8f7
DOI
10.1101/2025.02.02.25321552
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy of Tenapanor in Managing Hyperphosphatemia and Constipation in Hemodialysis Patients: A Randomized Controlled TrialDOI 10.1101/2025.02.02.25321552
Select a neighboring publication to make it the new centre.